Special Issue "Development of Targeted Therapies for the Clinical Management of Cancer"
A special issue of Sci (ISSN 2413-4155).
Deadline for manuscript submissions: closed (15 October 2020) | Viewed by 5735
2. Epidemiology Section, Colorado School of Public Health, Fort Collins, CO 80523, USA
3. Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523, USA
Interests: molecular genetics; epigenetic factors of disease; cultural and environmental factors of disease
Special Issues, Collections and Topics in MDPI journals
Special Issue in Veterinary Sciences: Educating the Future of Veterinary Science and Medicine
Special Issue in Diseases: Epigenetics and Disease
Special Issue in Education Sciences: Undergraduate Research as a High Impact Practice in Higher Education
Special Issue in Veterinary Sciences: Epigenetic Factors of Embryological Development and Tumorigenesis
Special Issue in Diseases: Epigenetics and Disease II
Special Issue in Sci: One Health
The development of targeted therapeutics has revolutionized the approach to targeting cancer in a way that minimizes the adverse side-effects associated with broad-spectrum applications. For example, small molecule enzyme inhibitors and monoclonal antibodies can be designed to target the specific biomolecules involved in tumorigenic cascades. In this Special Issue of Sci, we invite papers related to the design, development, testing, and regulatory approval pathways associated with targeted oncology therapeutics. Potential topics include, but are not limited to, the following:
- Identification of cancer-specific targets
- Methods for oncology therapeutic design
- Types of targeted therapeutics
- Gene targets
- Protein targets
- Small molecule inhibitors
- Monoclonal antibodies
- Targeting tumor-specific proliferation
- Targeting angiogenic pathways
- Targeting tumorigenic signal transduction
- Special regulatory pathways for approval of targeted therapeutics
Prof. Mark Brown
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Sci is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Targeted therapy
- Small molecular inhibitors
- Monoclonal antibodies
- Gene targeting.